精准医学时代乳腺癌内乳前哨淋巴结活检适应证的探讨
前瞻性纳入2014年2月至2017年9月山东省肿瘤医院乳腺病中心126例临床腋窝淋巴结阳性原发乳腺癌患者,在新型注射技术引导下行内乳前哨淋巴结活检(IM-SLNB)。94例(74.6%)内乳淋巴显像并成功活检,内乳前哨淋巴结转移率38.3%(36/94),与腋窝阳性淋巴结数目(P<0.001)和肿瘤大小(P=0.024)相关;36例阳性者行内乳放疗,58例阴性者避免放疗。作者认为临床腋窝淋巴结阳性患者应常规行IM-SLNB。
要点
- 126例临床腋窝淋巴结阳性乳腺癌患者中94例(74.6%)内乳淋巴显像并成功行IM-SLNB。
- 内乳前哨淋巴结转移率38.3%(36/94),与腋窝阳性淋巴结数目(P<0.001)及肿瘤大小(P=0.024)相关。
- 36例内乳前哨淋巴结阳性者行内乳放疗,58例阴性者避免内乳放疗。
核心结论
- 作者认为IM-SLNB应常规在临床腋窝淋巴结阳性的乳腺癌患者中实施,以指导更准确的淋巴分期和个体化放疗策略。
研究设计与样本
- 前瞻性研究,纳入2014年2月至2017年9月山东省肿瘤医院乳腺病中心临床腋窝淋巴结阳性的126例原发乳腺癌患者,在新型注射技术引导下经肋间行IM-SLNB。
主要发现
- 126例中94例(74.6%)有内乳前哨淋巴结显像,均成功接受IM-SLNB。
- 内乳血管损伤发生率为4.3%(4/94),胸膜损伤发生率为9.6%(9/94)。
- 内乳前哨淋巴结转移率为38.3%(36/94),与腋窝淋巴结阳性数目(P<0.001)和肿瘤大小(P=0.024)均有关。
- 94例行IM-SLNB患者均获得更准确的淋巴分期,其中36例内乳前哨淋巴结阳性患者行内乳放疗,58例阴性患者避免内乳放疗。
临床怎么用
- 作者认为IM-SLNB应常规在临床腋窝淋巴结阳性的乳腺癌患者中实施。
- 作者认为IM-SLNB可指导更准确的淋巴分期和个体化内乳放疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To determine the clinical benefits of internal mammary sentinel lymph node biopsy (IM-SLNB) acquired by breast cancer patients with clinically positive axillary lymph node (ALN), and further optimize the IM-SLNB indications. Methods: All primary breast cancer patients with clinically positive ALN from February 2014 to September 2017 were prospectively recruited in this study. IM-SLNB was performed under the guidance of the modified injection technique. The success rate and visualization rate of IM-SLNB, metastatic rate of internal mammary sentinel lymph node (IMSLN) and its related factors were analyzed, and the clinical benefits were accessed according to the current guidelines. Results: Among 126 patients, all of 94 patients (74.6%) who showed internal mammary drainage successfully underwent IM-SLNB. The incidence of internal mammary artery bleeding and pleural lesion were 4.3%(4/94) and 9.6%(9/94), respectively. The metastatic rate of IMSLN was 38.3% (36/94), which was significantly associated with the number of positive ALN (P<0.001) and tumor size (P=0.024). The lymph node staging of 94 patients who underwent IM-SLNB was more accurate. Among them, 36 cases with positive IMSLN underwent internal mammary radiotherapy (IMRT), while the other 58 cases with negative IMSLN avoided radiotherapy. Conclusions: IM-SLNB should be routinely performed in patients with positive ALN. IM-SLNB can provide more accurate staging and guide tailored IMRT to benefit more breast cancer patients. 目的: 探讨乳腺癌内乳前哨淋巴结活检(IM-SLNB)在临床腋窝淋巴结阳性患者中的临床效果,进一步优化IM-SLNB的适应证。 方法: 前瞻性研究2014年2月至2017年9月,就诊于山东省肿瘤医院乳腺病中心、临床腋窝淋巴结阳性的126例原发乳腺癌患者的临床资料,在新型注射技术引导下经肋间行IM-SLNB,分析IM-SLNB成功率、显像率、内乳前哨淋巴结(IMSLN)转移率及其相关因素,根据乳腺癌临床实践指南评估其临床获益。 结果: 126例患者中,94例(74.6%)有IMSLN显像,均成功接受IM-SLNB,内乳血管和胸膜损伤的发生率分别为4.3%(4/94)和9.6%(9/94)。IMSLN转移率为38.3%(36/94),与腋窝淋巴结阳性数目(P<0.001)和肿瘤大小(P=0.024)均有关。94例行IM-SLNB患者均可获得更准确的淋巴分期,其中36例IMSLN阳性患者行内乳放疗,58例IMSLN阴性患者避免内乳放疗。 结论: IM-SLNB应常规在临床腋窝淋巴结阳性的乳腺癌患者中实施,以指导更准确的淋巴分期,制订个体化放疗策略,使更多的乳腺癌患者获益。.
引用
- Wang YS, Zhao RR, Liu YB, et al. [Discussion on the indications of internal mammary sentinel lymph node biopsy in breast cancer in the era of precision medicine]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31014049. doi:10.3760/cma.j.issn.0253-3766.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。